Search Results

Curium Acquires Belgium's Abscint, Expanding HER2-Targeted Gallium-68 PET Oncology Radiopharmaceutical Diagnostics Pipeline

On August 10, 2026, radiopharmaceutical company Curium announced the completion of its acquisition of Abscint SA, a Belgian clinical-stage radiopharmaceutical company. The transaction grants Curium global development, manufacturing, and commercialization rights to ABS-011, further expanding its oncology PET radiopharmaceutical diagnostics portfolio. ABS-011 is an investigational gallium-68-labeled positron emission tomography (PET) radiopharmaceutical diagnostic tracer targeting human epidermal growth factor receptor 2 (HER2). HER2 is an important biological target in multiple cancers, including breast cancer and gastric cancer. Based on available information, ABS-011 is designed to enable whole-body quantitative imaging of HER2 expression, and following further clinical development and regulatory approval, has the potential to provide more comprehensive HER2 status information for patient characterization and clinical assessment.

2026-08-11

GAO Report Urges DOE-EM to Learn from Canada, UK, France, and Belgium in Reshaping Nuclear Waste Cleanup Strategy

The U.S. Government Accountability Office (GAO) noted in a new report that countries such as Canada, France, and the United Kingdom have taken proactive measures in recent years to accelerate nuclear waste cleanup. The report recommends that the U.S. Department of Energy's Office of Environmental Management (DOE-EM) engage in strategic exchanges with these countries to identify and evaluate alternative approaches that could reduce risks, lower costs, or expedite cleanup activities. Currently, DOE-EM estimates its cleanup mission could cost between $641 billion and $840 billion and may not be completed until 2100. The report found that while DOE-EM has some level of exchange with other countries on nuclear cleanup, such exchanges are not strategic and lack proactive learning...

2026-08-04